文献速递系统性红斑狼疮

Caspase-1抑制剂减轻MRL-Faslpr小鼠肾病并延缓全身病变

Treatment with caspase-1 inhibitor diminishes kidney disease in MRL-Faslpr mice and delays systemic illness.
PubMed 文献 · RMD Open · 2025-12-23

本研究在MRL-Faslpr小鼠SLE模型中,从2.5至5.5月龄给予caspase-1抑制剂pralnacase或假处理,评估全身及肾脏指标。结果发现caspase-1抑制显著减轻全身炎症、淋巴结肿大和皮肤病变,降低蛋白尿、改善肾功能并减少肾脏病理,主要通过降低IL-18水平实现;IL-1受体拮抗剂无效。

要点

  • caspase-1抑制可改善MRL-Faslpr小鼠的全身和肾脏狼疮表现。
  • 疗效主要与抑制caspase-1活性、降低IL-18介导的炎症有关。
  • 发病后干预仍有效,但程度弱于发病前治疗。

核心结论

  • caspase-1抑制通过抑制IL-18介导的炎症有效改善MRL-Faslpr小鼠SLE的全身和肾脏表现,提示caspase-1是SLE和LN的潜在治疗靶点。

研究设计与样本

  • 雌性MRL-Faslpr小鼠从2.5至5.5月龄接受caspase-1抑制剂pralnacase或假处理,并设IL-1受体拮抗剂、pan-caspase抑制及发病后干预实验。

主要发现

  • caspase-1抑制显著减少MRL-Faslpr小鼠的全身炎症、淋巴结肿大和皮肤病变。
  • 治疗组蛋白尿减少、肾功能改善、肾脏病理减轻。
  • 治疗特异性靶向caspase-1活性,降低IL-18水平并减弱肾脏免疫细胞活化和浸润。
  • 选择性caspase-1抑制与pan-caspase抑制结果相当。
  • IL-1受体拮抗剂治疗未显著影响疾病进展,提示IL-18是主要致病驱动因素。

临床怎么用

  • 在SLE和狼疮肾炎治疗中,caspase-1/IL-18轴可能是有前景的干预靶点,值得进一步临床研究。

局限性

  • 证据来自MRL-Faslpr小鼠模型,尚未在人体中验证。
  • 发病后干预的疗效弱于发病前治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the therapeutic potential of caspase-1 inhibition in systemic lupus erythematosus (SLE) and lupus nephritis (LN) using the MRL-Faslpr mouse model. METHODS: Female Murphy Roths large (MRL)-Faslpr mice were treated with a caspase-1 inhibitor (pralnacase) or sham treatment from 2.5 to 5.5 months of age. Disease progression was assessed through analysis of systemic and renal parameters, including proteinuria, blood urea nitrogen, kidney histopathology and immune cell infiltration. Cytokine expression and caspase activity were measured to elucidate the mechanism of action. Additional experiments with interleukin (IL)-1 receptor antagonist and pancaspase inhibition treatment as well as post-disease onset intervention were conducted. RESULTS: Caspase-1 inhibition significantly reduced systemic inflammation, lymphadenopathy and skin lesions in MRL-Faslpr mice. Treated mice exhibited decreased proteinuria, improved renal function and reduced kidney pathology. The treatment specifically targeted caspase-1 activity, leading to decreased IL-18 levels as well as attenuated immune cell activation and infiltration in the kidneys. Selective caspase-1 inhibition showed comparable results with pancaspase inhibition. IL-1 receptor antagonist treatment did not significantly affect disease progression, suggesting IL-18 as the primary driver of pathology. Post-disease onset intervention with caspase-1 inhibition also showed efficacy, although to a lesser extent than pre-onset treatment. CONCLUSIONS: Caspase-1 inhibition effectively ameliorates both systemic and renal manifestations of SLE in MRL-Faslpr mice, primarily through suppression of IL-18-mediated inflammation. This study identifies caspase-1 as a promising therapeutic target for SLE and LN, warranting further investigation in clinical trials.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Claßen P, Meineck M, Plath M, et al. Treatment with caspase-1 inhibitor diminishes kidney disease in MRL-Faslpr mice and delays systemic illness. RMD Open. 2025. PMID: 41436137. doi:10.1136/rmdopen-2025-006194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。